High-Yield Bioproduction of Virus-Free Virus-Like P4-EKORhE Multi-Lysin Transducing Particles
Harnessing Virus-like particles for Advanced Antimicrobial Delivery
Table of Contents
- Harnessing Virus-like particles for Advanced Antimicrobial Delivery
- Harnessing Virus-Like Particles for Advanced Antimicrobial Delivery: A Q&A Guide
- What are Virus-Like Particles (VLPs) and Why Use Them for Antimicrobial Delivery?
- What is P4-EKORhE and How is it Used in this Research?
- What is a multi-Lysins Cassette and How Does it Work?
- How Was the Antimicrobial Efficacy of the Multi-Lysins Cassette Tested?
- What Bioprocess Innovations are Highlighted in This Study?
- What are the Potential Applications of This Technology?
- What are the Competing Interests Declared in This Study?
- Summary of Key Aspects of P4-EKORhE-Mediated Antimicrobial Delivery
Innovative research details the creation of bioengineered P4-EKORhE particles and a robust method for achieving exceptionally high yields, reaching up to 1012 particles per milliliter. This breakthrough facilitates the use of virus-like particles to transduce genetically encoded antimicrobials, merging synthetic biology with optimized upstream and downstream processing techniques.
The Power of Multi-Lysins Cassettes
The resulting product, a gene-delivered antimicrobial in the form of the multi-lysins cassette, remains fully functional both before and after being packaged within P4-EKORhE particles. The antimicrobial efficacy of the multi-lysins cassette, defined by its lysis proteins, underwent rigorous testing.
In vivo Testing and Results
The testing occurred in vivo, utilizing both pure bacterial Escherichia coli (E. coli) cultures and an infection model employing A549 immortalized human epithelial tissue cell cultures. This comprehensive approach highlights several bioproduction methods.
Bioprocess Innovation
This work demonstrates how the virology of the P4 and P2 phages can be effectively utilized to establish a bioprocess for producing transducing particles at very high yields. This process avoids contamination by the natural virus while preserving the antimicrobial effectiveness of the final product.
Abstract Summary
The study focuses on the construction of the bioengineered P4-EKORhE and a comprehensive method for producing very high yields (up to 1012 particles per millilitre) enable the use of virus-like particles to transduce genetically encoded antimicrobials thru a combination of synthetic biology and optimised upstream and downstream processing. The final product, a gene-delivered antimicrobial in the form of the multi-lysins cassette, is fully functional before and after packaging within P4-ekorhe particles. The antimicrobial activity of the multi-lysins cassette, characterized by its lysis proteins, was tested in vivo in both pure bacterial Escherichia coli (E. coli) cultures and in a model of infection using A549 immortalised human epithelial tissue cell cultures. this work exemplifies several bioproduction methods and demonstrates how the virology of the P4 and P2 phages can be harnessed to establish a bioprocess for producing transducing particles at very high yields, avoiding contamination by the natural virus while maintaining the antimicrobial effectiveness of the final product.
Competing Interests
It is indeed significant to note the following disclosure:
R.R.G. is the founder of ACGTx (formerly Genova Tx). The othre authors declare no conflicts of interest.
Harnessing Virus-Like Particles for Advanced Antimicrobial Delivery: A Q&A Guide
This article delves into innovative research leveraging virus-like particles (VLPs) for advanced antimicrobial delivery. We’ll explore the creation of bioengineered P4-EKORhE particles, their production process, and their potential in combating bacterial infections.
What are Virus-Like Particles (VLPs) and Why Use Them for Antimicrobial Delivery?
Virus-like particles (VLPs) are structures that mimic viruses but do not contain any viral genetic material.This means they can enter cells, but they cannot replicate or cause infection. VLPs are used for antimicrobial delivery as of the following reasons.
Targeted Delivery: VLPs can be engineered to target specific cells or bacteria, delivering antimicrobials directly to the site of infection.
Enhanced Stability: Encapsulating antimicrobials within VLPs can protect them from degradation, increasing their effectiveness.
Reduced Toxicity: VLPs can reduce the toxicity of antimicrobials by controlling their release and preventing them from affecting healthy cells.
What is P4-EKORhE and How is it Used in this Research?
P4-EKORhE is a bioengineered virus-like particle derived from the P4 and P2 phages. In this research, P4-EKORhE serves as a delivery vehicle for genetically encoded antimicrobials. The researchers developed a robust method to produce P4-EKORhE at exceptionally high yields (up to 1012 particles per milliliter).
What is a multi-Lysins Cassette and How Does it Work?
A multi-lysins cassette is a collection of genes encoding lysis proteins. Lysis proteins are enzymes that break down bacterial cell walls,causing the bacteria to die. In this study, the multi-lysins cassette is the genetically encoded antimicrobial being delivered by the P4-EKORhE particles. The cassette’s antimicrobial efficacy is persistent by the effectiveness of its lysis proteins. The multi-lysins cassette, delivered by P4-EKORhE particles, effectively kills bacteria by disrupting their cell walls.
How Was the Antimicrobial Efficacy of the Multi-Lysins Cassette Tested?
The antimicrobial efficacy of the multi-lysins cassette was rigorously tested in vivo using the following.
Pure Bacterial Cultures: Escherichia coli (E. coli) cultures were used to assess the direct antibacterial effect of the multi-lysins cassette.
Infection Model: A549 immortalized human epithelial tissue cell cultures were infected wiht bacteria to simulate a real-world infection scenario and evaluate the cassette’s effectiveness in a more complex surroundings.
Complete Approach: This dual-testing approach ensured a thorough understanding of the antimicrobial’s capabilities in both controlled and simulated infection conditions.
What Bioprocess Innovations are Highlighted in This Study?
This study showcases several bioprocess innovations that include the following.
High-Yield Production: A method for producing transducing particles at very high yields (up to 1012 particles per milliliter) was developed.
Contamination Prevention: The bioprocess avoids contamination by the natural virus,ensuring the purity of the final product.
Antimicrobial Effectiveness: The process maintains the antimicrobial effectiveness of the final product.
Phage Virology Utilization: The process effectively utilizes the virology of the P4 and P2 phages to establish a bioprocess for producing transducing particles.
What are the Potential Applications of This Technology?
This technology has numerous potential applications in combating bacterial infections, including the following.
targeted Antibacterial Therapy: Delivering antimicrobials directly to the site of infection could improve treatment outcomes and reduce side effects.
Combating Antibiotic Resistance: New antimicrobials delivered via VLPs could help overcome antibiotic resistance.
Development of Novel Antimicrobial Agents: The VLP delivery system can be used to deliver other novel antimicrobial agents.
Ophthalmic Drug Delivery: Polymeric particles,similar to VLPs,can be adapted for sustained drug release in the eye,penetrating the cornea for effective treatment (as noted in web search result [1]).
Targeted Delivery to Specific Tissues: Liposomes and VLPs can be directed to specific tissues,organs,or even targeted to specific pathogenic bacteria,enhancing the delivery of antimicrobial agents (as noted in web search result [2]).
What are the Competing Interests Declared in This Study?
one of the researchers (R.R.G.) is the founder of ACGTx (formerly Genova Tx). The other authors declare no conflicts of interest. This disclosure provides transparency regarding potential biases and allows for a more objective assessment of the research findings.
Summary of Key Aspects of P4-EKORhE-Mediated Antimicrobial Delivery
| Feature | Description |
| —————————- | —————————————————————————————————————————————————– |
| Delivery Vehicle | Bioengineered P4-EKORhE virus-like particles |
| antimicrobial Payload | multi-lysins cassette (genetically encoded lysis proteins) |
| Production Yield | Up to 1012 particles per milliliter |
| Target bacteria | Escherichia coli (E. coli) |
| Testing Methods | In vivo* testing on pure bacterial cultures and A549 immortalized human epithelial tissue cell cultures |
| key Benefits | High-yield production, contamination prevention, maintenance of antimicrobial effectiveness, potential for targeted antibacterial therapy |
| Competing Interests | R.R.G. is founder of ACGTx (formerly Genova Tx); other authors declare no conflicts |